Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy.
Xin Shelley Wang; Loretta A Williams; Sunil Krishnan; Zhongxing Liao; Ping Liu; Li Mao; Qiuling Shi; Gary M Mobley; Jeanie F Woodruff; Charles S Cleeland (Profiled Author: Li Mao)
Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. xswang@mdanderson.org
Brain, behavior, and immunity 2012;26(5):699-705.
Although evidence of inflammation and fatigue has been noted in cancer survivors, whether inflammation is linked to the expression of fatigue and other symptoms arising from concurrent chemoradiation therapy (CXRT) has not been well studied. Patients undergoing CXRT for locally advanced colorectal or esophageal cancer (n=103) reported multiple symptoms weekly via the M. D. Anderson Symptom Inventory (MDASI) from start of therapy. Serum samples were collected weekly to examine changes in inflammatory markers (interleukin (IL)-6, IL-8, IL-10, IL-1 receptor antagonist (IL-1RA), vascular endothelial growth factor (VEGF), and soluble receptor 1 for tumor necrosis factor (sTNF-R1)) via enzyme-linked immunosorbent assay. Relationships between symptom severity and inflammatory-marker concentration levels were estimated using mixed-effect regression analysis, controlled for week of therapy, age, sex, body mass index, pre-CXRT tumor stage, pre-CXRT chemotherapy, pre-CXRT statin use, and type of cancer. Fatigue was the most severe symptom over time, its development profile shared with pain, distress, drowsiness, poor appetite, and disturbed sleep. sTNF-R1 and IL-6 shared a similar pattern of symptom development, with significant increase during CXRT and decrease after completion of CXRT. Serum concentrations of sTNF-R1 were positively associated over time with the severity of fatigue (p=0.00097), while sTNF-R1 and IL-6 were positively related to the severity of a component score of the six most severe symptoms (both p<0.0001). This longitudinal study suggests a role for over-expressed sTNF-R1 and IL-6 in the development of fatigue and other severe sickness symptoms during CXRT in patients with colorectal or esophageal cancer.
Scientific Context
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Related Publications
-
1.
2010Xin Shelley Wang; Qiuling Shi; Loretta A Williams; Li Mao; Charles S Cleeland; Ritsuko R Komaki; Gary M Mobley; Zhongxing Liao
Brain, behavior, and immunity 2010;24(6):968-74. -
2.
2010Sarah E Tom; Diana Kuh; Jack M Guralnik; Gita D Mishra
Menopause (New York, N.Y.) 2010;17(6):1128-35. -
3.
2009S E Tom; D Kuh; J M Guralnik; G D Mishra
Journal of epidemiology and community health 2009;63(12):974-9.
Related Topics
Appears in this Publication
Related Experts
Author of this Publication
-
Internal ExpertsPublications
-
167









-
8









-
67









-
248









-
83









-
243










